Abera Bioscience (ABERA) Stock Overview
A platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ABERA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Abera Bioscience AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 7.20 |
| 52 Week High | SEK 9.70 |
| 52 Week Low | SEK 3.72 |
| Beta | 1.01 |
| 1 Month Change | 6.67% |
| 3 Month Change | 7.46% |
| 1 Year Change | 77.34% |
| 3 Year Change | 38.46% |
| 5 Year Change | n/a |
| Change since IPO | -34.84% |
Recent News & Updates
Shareholder Returns
| ABERA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 10.8% | -1.5% | 0.2% |
| 1Y | 77.3% | -8.1% | 6.7% |
Return vs Industry: ABERA exceeded the Swedish Biotechs industry which returned -8.1% over the past year.
Return vs Market: ABERA exceeded the Swedish Market which returned 6.7% over the past year.
Price Volatility
| ABERA volatility | |
|---|---|
| ABERA Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 2.9% |
Stable Share Price: ABERA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ABERA's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 5 | Maria Alriksson | aberabio.com |
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.
Abera Bioscience AB Fundamentals Summary
| ABERA fundamental statistics | |
|---|---|
| Market cap | SEK 132.82m |
| Earnings (TTM) | -SEK 1.45m |
| Revenue (TTM) | SEK 17.30m |
Is ABERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABERA income statement (TTM) | |
|---|---|
| Revenue | SEK 17.30m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 17.30m |
| Other Expenses | SEK 18.75m |
| Earnings | -SEK 1.45m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.079 |
| Gross Margin | 100.00% |
| Net Profit Margin | -8.41% |
| Debt/Equity Ratio | 0% |
How did ABERA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/05 09:18 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abera Bioscience AB is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Niklas Elmhammer | Carlsquare AB |
| Herman Kuntscher | Carlsquare AB |